Amryt Pharma PLC (NASDAQ:AMYT; LON:AMYT) hailed as a “significant milestone” the phase III success of FILSUVEZ, a gel for a rare and extremely painful skin condition called epidermolysis bullosa (EB).
The study achieved its main goal, known in the scientific parlance as the primary endpoint, of accelerating the wound healing process
The next step is a rolling submission programme to the regulatory authorities, with the company applying for speedy approval in both the US and EU.
It previously received fast track designation and rare paediatric disease designation from America’s Food & Drug Administration, and it expects to be eligible to apply for a rare paediatric disease priority review voucher.
Submissions to the US and EU regulators are expected to be made late in the first quarter of next year.
The full set of data will be fully assessed and presented to an upcoming scientific symposium, Amryt said.
In all 223 people were enrolled onto the phase III EASE trial, 156 of them children or infants.
It was a double-blind study in which one group received the active treatment while the other didn’t. Only at the end did doctors know which group was which.
The Amryt team then compared total wound closer over 45 days of treatment across the two groups. The results were highly statistically significant.
Chief executive, Dr Joe Wiley, said: “We are proud to present these positive and encouraging results, demonstrating that FILSUVEZ could make an important difference to the lives of patients.
“We would like to extend our gratitude to all of the patients, their families, carers and physicians for their participation in the EASE trial and we look forward to working with regulatory authorities to make FILSUVEZ available as the first approved therapeutic treatment for EB patients.
“All of the team at Amryt are very excited by today’s news and the impact this may have in our efforts to help patients with this very distressing condition.”
EB is a rare, chronic and distressing genetic skin disorder that causes the skin layers and internal body linings to separate.
Amryt estimates there are as many as 30,000 youngsters and adults affected by it in the US and there are 500,000 sufferers worldwide.
The potential market for FILSUVEZ, therefore, is in excess of US$1bn.
Story by ProactiveInvestors
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com
Order by Phone at 888-809-8385 or online at https://www.herbanomic.com
Get our Free Ebook, "Suppressed Health Secrets" with Natural Cures THEY don't want you to know!
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
pathogens and gives you more
energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Organic Hemp Extract (CBD) - Full Spectrum high CBD (3300mg) hemp extract eases stiff joints, relieves stress and more!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video)
Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.